Acta Pharmaceutica Sinica B
|
2026, 16(2): 1166-1167
• Commentaries •
A highly promising new avenue for targeting K-RAS: The small-molecule degrader XMU-MP-9
Full
Jian Jin1,2,3
Affiliations
1 Mount Sinai Center for Therapeutics Discovery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA;
2 Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA;
3 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
doi: 10.1016/j.apsb.2026.01.012
Outline
K-Ras mutants
/
NEDD4-1
/
Small-molecule degrader
/
Bifunctional compound
/
Ubiquitination
/
Degradation
Jian Jin.
A highly promising new avenue for targeting K-RAS: The small-molecule degrader XMU-MP-9[J].
Acta Pharmaceutica Sinica B,
2026
, 16
(2)
: 1166
-1167
.
DOI: 10.1016/j.apsb.2026.01.012
Year 2026 volume 16 Issue 2
PDF
5
3
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.apsb.2026.01.012